VLA.PA stock opens pre-market at €4.93 as investors position ahead of Valneva SE’s full-year 2025 results and webcast scheduled for 18 March 2026. Trading shows 2,726,316.00 shares today vs average volume 989,633.00, signaling higher interest. Key near-term drivers include FY2025 revenue and margin detail, cash runway commentary, and clinical updates on VLA15 and VLA1553 that can move sentiment in EUR on the EURONEXT market.
Earnings preview: what VLA.PA stock needs to show
Valneva reports FY2025 results on 18 March 2026 and the market will watch three items. First, commercial vaccine sales trends for IXIARO and DUKORAL will show recurring cash flow. Second, R&D spend and timing on VLA15 (Lyme) and VLA1553 (chikungunya) will affect guidance. Third, operating cash flow and free cash flow guidance will drive near-term liquidity signals. Each item links directly to valuation and the stock’s short-term move on EURONEXT.
Financials and valuation: current metrics versus sector
Valneva shows a trailing EPS of -0.65 and a negative PE of -7.58, with market cap roughly €847,708,828.00. Price-to-book is 5.32 versus the Healthcare sector average PB near 2.64, flagging a relative premium. Operating margins remain negative at about -43.52% and current ratio 1.78, so cash flow and debt metrics will be central to any positive read-through from earnings.
Meyka AI rates VLA.PA with a score out of 100
Meyka AI rates VLA.PA with a score out of 100: 61.76 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade reflects improving revenue growth but continued negative profitability and higher price-to-book. These grades are not guaranteed and are not financial advice.
Meyka AI’s forecast model and price scenarios for VLA.PA stock
Meyka AI’s forecast model projects a 12-month central price of €5.04, implying +2.26% vs the current €4.93. The model gives a bullish quarterly scenario €5.73 (+16.23%) and a near-term bearish monthly scenario €3.86 (-21.70%). Forecasts are model-based projections and not guarantees. Use these levels as scenario anchors when sizing risk around the earnings date.
Technicals and trading cues for VLA.PA stock
Short-term indicators show RSI 61.19, MACD histogram near -0.01, and Bollinger upper band 5.09. Price sits above the 50-day average €4.29 and 200-day average €3.80, which supports a constructive momentum bias. Volume is notable at 2,726,316.00 today (rel volume 2.75), suggesting the market is already repricing ahead of results.
Risks and catalysts shaping the earnings reaction
Risks include clinical trial delays, unexpected regulatory feedback, and weaker vaccine sales. Catalysts that could lift the stock are stronger-than-expected IXIARO sales, improved operating cash flow, and positive updates on VLA15 or VLA1553. Watch management commentary during the 18 March webcast for funding plans and next milestones, which will set the tone for trading on EURONEXT in EUR.
Final Thoughts
Key takeaways for VLA.PA stock: investors face a narrow near-term upside but clear event risk at the FY2025 report on 18 March 2026. The shares trade at €4.93 with an average 50-day of €4.29 and year high €5.42. Meyka AI’s forecast model projects €5.04 (12-month central, +2.26% implied) with a bullish scenario at €5.73 (+16.23%) and a bearish near-term level of €3.86 (-21.70%). Valuation shows a premium PB of 5.32 vs Healthcare peers, and profitability remains negative (EPS -0.65). Traders should weigh liquidity and trial timelines against potential upside from better commercial sales or clinical progress. Meyka AI, an AI-powered market analysis platform, highlights liquidity, upcoming guidance, and R&D milestones as the critical levers. Forecasts are model-based projections and not guarantees; consider position sizing and stop levels around the earnings event.
FAQs
When does Valneva report earnings and how will it affect VLA.PA stock?
Valneva will report FY2025 results on 18 March 2026. The report can move VLA.PA stock on sales for IXIARO and DUKORAL, R&D spend, and cash flow guidance. Expect volatility around the webcast and guidance comments.
What price targets and forecasts exist for VLA.PA stock?
Meyka AI projects a central 12-month price of €5.04 (+2.26%), a bullish quarterly scenario €5.73 (+16.23%) and a near-term bearish €3.86 (-21.70%). These are model projections and not guarantees.
Is Valneva overvalued versus its sector for VLA.PA stock?
On price-to-book, VLA.PA at 5.32 is above the Healthcare sector PB near 2.64, indicating a premium. Negative margins and EPS -0.65 underline the valuation risk until profitability improves.
What are the top catalysts to watch for VLA.PA stock after earnings?
Key catalysts include management guidance on cash flow, reported vaccine sales trends, and clinical updates for VLA15 and VLA1553. Funding plans or partnerships could also change the outlook materially.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask our AI about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)